Stocks and InvestingStocks and Investing
Thu, October 5, 2023
Wed, October 4, 2023
Tue, October 3, 2023

Joel Beatty Maintained (SNDX) at Buy with Decreased Target to $28 on, Oct 3rd, 2023


Published on 2024-10-28 06:41:25 - WOPRAI, Joel Beatty
  Print publication without navigation


Joel Beatty of Baird, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Buy with Decreased Target from $32 to $28 on, Oct 3rd, 2023.

Joel has made no other calls on SNDX in the last 4 months.



There are 8 other peers that have a rating on SNDX. Out of the 8 peers that are also analyzing SNDX, 0 agree with Joel's Rating of Hold.



These are the ratings of the 8 analyists that currently disagree with Joel


  • Edward White of "HC Wainwright & Co." Reiterated at Strong Buy with Increased Target to $42 on, Monday, October 2nd, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $33 on, Wednesday, August 16th, 2023
  • George Farmer of "Scotiabank" Initiated at Buy and Held Target at $39 on, Thursday, July 27th, 2023
  • Peter Lawson of "Barclays" Maintained at Buy with Increased Target to $34 on, Wednesday, July 26th, 2023
  • Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Increased Target to $35 on, Wednesday, July 26th, 2023
  • Kalpit Patel of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $36 on, Tuesday, July 25th, 2023
  • Michael Schmidt of "Guggenheim" Maintained at Strong Buy with Increased Target to $42 on, Tuesday, July 25th, 2023
  • Justin Zelin of "BTIG" Maintained at Strong Buy with Increased Target to $35 on, Monday, June 26th, 2023